consistent ~12-15% weight loss at 68 weeks Compound Tirzepatide (Zepbound) Class GIP/GLP-1 dual agonist FDA Status FDA-approved for chronic weight management Evidence Strength Phase 3 RCTs
And there can be very real negative side effectsnausea, fatigue, dizziness, muscle and hair lossand some people have even reported increased depression and suicidal ideation, although a large-scale meta study seemed to show no direct link to the medication itself
What Needs Monitoring A responsible protocol is a monitored protocol
Some pharmacists are choosing not to stock the drug at all [Internet]
If cost is a concern, discuss this openly with your pharmacist or healthcare providerpatient assistance programs or manufacturer savings cards may be available
I'm Anu Sharma, a board-certified Psychiatric Mental Health Nurse Practitioner (PMHNP-BC) committed to helping children, adolescents, and adults achieve better mental health through compassionate, evidence-based care